Kockler D R, McCarthy M W, Lawson C L
Department of Pharmacy Services, Drug Information Center, University of Virginia Health System, Charlottesville 22908-0674, USA.
Pharmacotherapy. 2001 May;21(5):647-51. doi: 10.1592/phco.21.6.647.34542.
A 22-year-old man was hospitalized after unexplained seizure-like activity and unresponsiveness. A urine toxicology screen was negative for salicylates, acetaminophen, alcohol, and drugs of abuse. Medical history was insignificant with the exception of recent (within 2 wks) ingestion of Hydroxycut is a dietary supplement purported to be energy enhancing, muscle building, and fat burning. The agent contains ephedra alkaloids and caffeine, which are both central nervous system stimulants; the etiology of seizure was attributed to their consumption. Due to a significant number of reported adverse events, the United States Food and Drug Administration (FDA) proposed regulations for dietary supplements containing ephedra alkaloids and requested an independent review of case reports linked to these products. Because herbal products are not subject to the same rigorous FDA regulations required for prescription and over-the-counter products, consumers unknowingly risk adverse effects when taking these products. Questioning patients about consumption of herbal products should be part of routine medical visits.
一名22岁男子在出现不明原因的癫痫样活动和无反应后住院。尿液毒理学筛查显示水杨酸盐、对乙酰氨基酚、酒精及滥用药物均为阴性。除了近期（两周内）服用Hydroxycut外，其病史无特殊意义。Hydroxycut是一种声称具有增强能量、增肌和燃烧脂肪作用的膳食补充剂。该制剂含有麻黄生物碱和咖啡因，二者均为中枢神经系统兴奋剂；癫痫发作的病因被认为与服用它们有关。由于有大量关于不良事件的报告，美国食品药品监督管理局（FDA）提议对含有麻黄生物碱的膳食补充剂制定相关规定，并要求对与这些产品相关的病例报告进行独立审查。由于草药产品不像处方药和非处方药那样受到FDA同样严格的监管，消费者在服用这些产品时会在不知不觉中面临不良反应的风险。询问患者是否服用草药产品应成为常规医疗问诊的一部分。
